Search

Your search keyword '"Ando, Nobuhisa"' showing total 23 results
Start Over Author "Ando, Nobuhisa"
23 results on '"Ando, Nobuhisa"'

1. Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer

Author

Tanaka, Kentaro, primary, Chamoto, Kenji, additional, Saeki, Sho, additional, Hatae, Ryusuke, additional, Ikematsu, Yuki, additional, Sakai, Kazuko, additional, Ando, Nobuhisa, additional, Sonomura, Kazuhiro, additional, Kojima, Shinsuke, additional, Taketsuna, Masanori, additional, Kim, Young Hak, additional, Yoshida, Hironori, additional, Ozasa, Hiroaki, additional, Sakamori, Yuichi, additional, Hirano, Tomoko, additional, Matsuda, Fumihiko, additional, Hirai, Toyohiro, additional, Nishio, Kazuto, additional, Sakagami, Takuro, additional, Fukushima, Masanori, additional, Nakanishi, Yoichi, additional, Honjo, Tasuku, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

5. Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer

Author

Furukawa, Rie, primary, Inoue, Hiroyuki, additional, Yoneshima, Yasuto, additional, Tsutsumi, Hirono, additional, Iwama, Eiji, additional, Ikematsu, Yuki, additional, Ando, Nobuhisa, additional, Shiraishi, Yoshimasa, additional, Ota, Keiichi, additional, Tanaka, Kentaro, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2021
Full Text
View/download PDF

6. Association of Mps one binder kinase activator 1 ( MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer

Author

Ando, Nobuhisa, primary, Tanaka, Kentaro, additional, Otsubo, Kohei, additional, Toyokawa, Gouji, additional, Ikematsu, Yuki, additional, Ide, Maako, additional, Yoneshima, Yasuto, additional, Iwama, Eiji, additional, Inoue, Hiroyuki, additional, Ijichi, Kayo, additional, Tagawa, Tetsuzo, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2020
Full Text
View/download PDF

9. Abstract 2412: Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment

Author

Rie Furukawa, Isamu Okamoto, Hirono Tsutsumi, Keiichi Oota, Eiji Iwama, Kentaro Tanaka, Hiroyuki Inoue, Yasuto Yoneshima, Yoichi Nakanishi, Ando Nobuhisa, and Yuki Ikematsu

Subjects
Cisplatin, Cancer Research, business.industry, non-small cell lung cancer (NSCLC), Combination chemotherapy, Vinorelbine, medicine.disease, Pemetrexed, Oncology, Docetaxel, medicine, Cancer research, Immunogenic cell death, business, Lung cancer, medicine.drug
Abstract

Recent clinical trials have shown that the addition of immune checkpoint inhibitors (ICIs)–such as antibodies to PD-1 or to PD-L1–to platinum-based combination chemotherapy resulted in a significant extension of overall survival in patients with advanced non-small cell lung cancer (NSCLC). This synergistic effect is possibly attributable in part to the phenomenon of immunogenic cell death (ICD), which is characterized by the release of danger-associated molecular patterns (DAMPs) from dying tumor cells. Calreticulin (CRT) is one of the most potent DAMPs and its cell surface translocation (ecto-CRT) serves as an “eat me” signal to antigen-presenting cells (APCs), which plays a pivotal role in activating anti-tumor immunity. However, there is limited information which chemotherapeutic agents used in the treatment of NSCLC can induce the expression of ecto-CRT most robustly on the surface of dying lung cancer cells. In current study, to identify the most effective inducer of ecto-CRT, using flow cytometry, we compared the expression levels of ecto-CRT on different 3 NSCLC cell lines treated with 9 chemotherapeutic agents including oxaliplatin (as positive control), cisplatin, carboplatin, pemetrexed, gemcitabine, 5-fluorouracil, docetaxel, paclitaxel and vinorelbine under each value of IC50 (0.0023 μM~25.2 μM) determined by MTS assay after 72 hours exposure to each chemotherapeutic agent. We found that pemetrexed induced the highest expression of ecto-CRT compared with other chemotherapeutic agents in all NSCLC cell lines examined. There are significant positive correlations between positive rates of ecto-CRT and annexin V, commonly used to detect apoptotic cells, in all NSCLC cell lines (r=0.79~0.95, p=0.0001~0.0088). In addition, pemetrexed-inducible expression of ecto-CRT on A549 cells was remarkably reduced when pan-caspase inhibitor z-VAD-fmk was added, illustrating its dependency on the caspase activity associated with apoptosis. Furthermore, using a syngeneic mouse tumor model that is moderately sensitive to anti-PD-1 therapy, we confirmed that combination treatment with pemetrexed enhanced the in vivo antitumor effect compared with anti-PD-1 or pemetrexed monotherapy. Notably, in clinical settings, we found that the plasma concentrations of soluble CRT collected from 3 NSCLC patients treated with pemetrexed alone were increased during the first cycle of treatment in all patents examined. Collectively, our findings showed that pemetrexed is the most effective inducer of ecto-CRT in NSCLC cell lines among numerous chemotherapeutic agents, suggesting that the combinational use of pemetrexed on ICIs therapy might exert synergistic antitumor immunity by triggering abundant expression of ecto-CRT in parallel to apoptosis induction in local tumor tissues of patients with advanced NSCLC. Citation Format: Rie Furukawa, Hiroyuki Inoue, Hirono Tsutsumi, Ando Nobuhisa, Yuki Ikematsu, Keiichi Oota, Eiji Iwama, Yasuto Yoneshima, Kentaro Tanaka, Yoichi Nakanishi, Isamu Okamoto. Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2412.

Published
2020

11. Patients with MAC Lung Disease Have a Low Visceral Fat Area and Low Nutrient Intake

Author

Wakamatsu, Kentaro, primary, Nagata, Nobuhiko, additional, Maki, Sanae, additional, Omori, Hisamitsu, additional, Kumazoe, Hiroyuki, additional, Ueno, Kayoko, additional, Matsunaga, Yuko, additional, Hara, Makiko, additional, Takakura, Koji, additional, Fukumoto, Nagisa, additional, Ando, Nobuhisa, additional, Morishige, Mami, additional, Akasaki, Takashi, additional, Inoshima, Ichiro, additional, Ise, Shinji, additional, Izumi, Miiru, additional, and Kawasaki, Masayuki, additional

Published
2015
Full Text
View/download PDF

21. Detection of Mutant Krasin Dissected Paraaortic Lymph Nodes of Patients with Pancreatic Adenocarcinoma

Author

Ando, Nobuhisa, Nakao, Akimasa, Nomoto, Shuji, Takeda, Shin, Kaneko, Tetsuya, Kurokawa, Tsuyoshi, Nonami, Toshiaki, and Takagi, Hiroshi

Abstract

In this study, we attempted to detect K-raspoint mutations by means of two-stage polymerase chain reaction/ restriction fragment length polymorphism (PCR/RFLP) to diagnose micrometastases in paraaortic lymph nodes of patients with pancreatic adenocarcinoma. Main carcinoma tissues and corresponding lymph nodes in the paraaortic region were obtained from 15 patients who underwent extended radical surgery including the wide dissection of lymph nodes and who were diagnosed as lymph node negative by routine histological examination. DNA was extracted from the tissue specimens, and PCR/RFLP analysis was used to detect K-rasoncogene mutations at codon 12. Thirteen of the primary tumors were found to have K-rasmutations. In eight of the 13 cases, 42 of the 101 lymph nodes showed K-raspoint mutations in the paraaortic lymph nodes. These results suggested that PCR/ RFLP analysis is potentially highly sensitive for the detection of micrometastases in lymph nodes and that it may be useful in reaching an accurate assessment of the lymphatic dissemination of pancreatic adenocarcinoma at the molecular level.

Published
1997

22. Clinical application of K-<TOGGLE>ras</TOGGLE> oncogene mutations in pancreatic carcinoma: Detection of micrometastases

Author

Nomoto, Shuji, Nakao, Akimasa, Ando, Nobuhisa, Takeda, Shin, Kasai, Yasushi, Inoue, Soichiro, Kaneko, Tetsuya, and Takagi, Hiroshi

Abstract

Pancreatic adenocarcinomas are known to have a high incidence of K-ras gene mutation. We summarize our efforts to detect micrometastases through a search for mutated K-ras oncogene in liver tissues, peritoneal washings, para-aortic lymph nodes, and perioperative peripheral blood. Two-stage polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis were used to detect K-ras oncogene mutations at codon 12. Our results suggest that PCR/RFLP analysis is potentially highly sensitive for the detection of micrometastases in various tissues and might be of value in the diagnosis, treatment and follow-up of metastases in other organs with pancreatic adenocarcinoma. Semin. Surg. Oncol. 15:40–46, 1998. © 1998 Wiley-Liss, Inc.

Published
1998
Full Text
View/download PDF

23. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].

Author

Mizuno Y, Chin K, Ando N, and Oike E

Subjects
Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, Female, Humans, Middle Aged, Paclitaxel administration & dosage, Remission Induction, Trastuzumab, Adenocarcinoma drug therapy, Adenocarcinoma metabolism, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Receptor, ErbB-2 biosynthesis
Abstract

A 57-year-old female was diagnosed as local, lung, and multiple liver metastases in the 2 years and 6 months after surgery. As expression of HER2 showed 3+, we performed trastuzumab/paclitaxel combination therapy. After 3 cycles, a rapid complete response was seen clinically. It is suggested that trastuzumab/paclitaxel combination therapy might be a first-line treatment for HER2 overexpressing recurrent breast cancer which had not been treated previously with anthracycline drugs.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results